Watch our Latest Webinar: "Unlocking the Glycoproteome: Utilizing a Robust AI/ML Based Platform for Biomarker Discovery"


InterVenn Biosciences to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced Company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17, 2022 at 2:30 p.m. Eastern Time.

The members of InterVenn’s executive leadership team will be available for one-on-one meetings at the event. A live and archived webcast of the event will be available on the “For Investors” section of the InterVenn website at following the forum.


InterVenn Contact
Ramuné Carothers
Vice President, Corporate Communications
InterVenn Biosciences

Investor Contact
David Deuchler, CFA
Gilmartin Group

Get in touch